A 35-year-old woman from rural Maharashtra undergoes cervical screening with liquid-based cytology and is found to have CIN II (cervical intraepithelial neoplasia grade 2). Regarding the natural history and management of CIN II, all of the following are true EXCEPT:

Explanation

## Natural History and Management of CIN II ### Overview of CIN II **Key Point:** CIN II is a high-grade cervical intraepithelial neoplasia with significant risk of progression to invasive cancer if untreated. Management is NOT expectant observation but active treatment. ### Correct Statements (Options 0, 1, 3) #### Option 0: Regression Rate of ~40% in 2 Years - **CIN I (low-grade):** Regression rate 50–60% within 2 years; many lesions regress spontaneously. - **CIN II (high-grade):** Regression rate ~30–40% in younger women (<25 years); lower in older women. - **CIN III:** Regression rate <5%; almost always requires treatment. **Clinical Pearl:** Even though CIN II can regress, the risk of progression to invasive cancer (5–30% if untreated) is substantial enough to warrant treatment in most cases. #### Option 1: Persistent HR-HPV Required for Progression **High-Yield:** Persistent infection with HR-HPV is the essential driver of progression from CIN to invasive carcinoma. - Viral clearance (which occurs in ~60% of CIN II cases) is associated with lesion regression. - Persistent HR-HPV infection is associated with progression risk of 5–30% over 5 years. - This is why HPV testing is used for triage and follow-up of CIN lesions. #### Option 3: HPV-16 and HPV-18 Have Higher Progression Risk | HPV Type | Prevalence in Cervical Cancer | Progression Risk | Clinical Significance | | --- | --- | --- | --- | | HPV-16 | ~50% | Highest | Most oncogenic; associated with adenocarcinoma | | HPV-18 | ~20% | High | Associated with adenocarcinoma and poor prognosis | | Other HR-HPV (31, 33, 45, 52, 58) | ~30% | Moderate to high | Lower progression rate than 16/18 | **Mnemonic:** **"16 and 18 are the meanest"** — HPV-16 and HPV-18 confer the highest risk of progression and invasive disease. ### The Incorrect Statement (Option 2) **Warning:** This is a dangerous misconception. LEEP/excisional procedures ARE indicated for CIN II, not contraindicated. **Key Point:** CIN II Management Strategy 1. **Treatment is standard of care** for CIN II in most women (especially age >25 years). 2. **Excisional procedures (LEEP, cold knife conization)** are first-line treatments because they: - Provide histological assessment of margins and rule out invasive disease. - Have high cure rates (90–95%). - Allow pathological examination of the entire lesion. 3. **Expectant management** (observation without treatment) is only considered in: - Young women (<25 years) with CIN I (not CIN II). - Specific clinical scenarios with close follow-up. 4. **Why not expectant for CIN II?** Although 30–40% regress, 5–30% progress to invasive cancer if untreated—an unacceptable risk. **Clinical Pearl:** The 2012 ASCCP (American Society for Colposcopy and Cervical Pathology) guidelines recommend treatment of CIN II in women ≥25 years. Observation may be considered only in women <25 years with CIN II if close follow-up is assured [cite:ASCCP 2012]. ### Management Algorithm for CIN II ```mermaid flowchart TD A[CIN II diagnosed on colposcopy]:::outcome --> B{Age?}:::decision B -->|≥25 years| C[Excisional procedure: LEEP/conization]:::action B -->|<25 years| D{Reliable follow-up?}:::decision D -->|Yes| E[May observe with HPV testing at 12 months]:::action D -->|No| F[Excisional procedure]:::action C --> G[Assess margins + rule out invasion]:::action E --> H{HPV negative?}:::decision H -->|Yes| I[Routine screening]:::outcome H -->|No| J[Repeat colposcopy or treatment]:::action F --> K[Post-treatment surveillance]:::action ```